VALENCIA, Calif., July 17, 2017 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) today announced that Steven Binder has joined the company as its Chief Financial Officer with full responsibilities for leading MannKind’s finance, accounting, and investor relations organization on a global basis, effective immediately. Mr. Binder will report directly to Michael Castagna, Pharm.D., Chief Executive Officer and will join the company’s executive leadership team.
Mr. Binder joins MannKind with over 25 years of experience in the healthcare industry. He most recently spent four years at Stryker Corporation, a leading global medical technology company, where he served as Vice President and Chief Financial Officer for Stryker’s International Group, based in Singapore. Prior to Stryker, Mr. Binder served in a series of senior leadership roles at Bristol-Myers Squibb Company, an innovative global biopharmaceutical company. His last four positions at BMS were Vice President, Finance roles over different geographic operating units: United States (2012-2013), Europe (2008-2011), AsiaPacific (2005-2007), and Japan (2003-2005). Prior to his international experience, Mr. Binder served in three senior leadership roles for Oncology Therapeutics Network, a U.S. based independent subsidiary of BMS: Vice President, Strategic Development (2001-2003), Vice President, Customer Operations (2000-2001), and Chief Financial Officer (1997-2000). Before OTN, Mr. Binder progressed through three finance and accounting roles for BMS Worldwide Medicines Group after joining the company in 1992. Before BMS, he worked for Deloitte & Touche in a series of auditing roles with increasing responsibility over an eight year period beginning in 1984. Mr. Binder received a B.S. degree in Accounting and Business Administration from Muhlenberg College and is a Certified Public Accountant.
“We are very excited to have Steve join MannKind and our executive leadership team. His deep experience in finance and his commercial acumen acquired through a variety of senior leadership roles in multi-national healthcare companies will be a clear competitive advantage for us,” said Dr. Castagna, Chief Executive Officer of MannKind. “Steve joins MannKind at an exciting period as we develop into a world class biopharmaceutical company.” Dr. Castagna continued, “I would like to thank Rose Alinaya for her leadership as Acting Chief Financial Officer prior to Steve’s hiring. Rose will now transition to leading investor relations for MannKind, a very important capability for us moving forward, reporting directly to Steve.”
Mr. Binder commented, “MannKind is well-positioned for future growth and I could not be more excited about being a part of this team. I believe Afrezza is an innovative product with great potential to improve the quality of life for diabetic patients.”
About MannKind Corporation
MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) focuses on the discovery and development of therapeutic products for patients with diseases such as diabetes. MannKind maintains a website at http://www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.
This press release contains forward-looking statements that involve risks and uncertainties, including statements regarding the commercial potential of Afrezza. Words such as “believes”, “anticipates”, “plans”, “expects”, “intend”, “will”, “goal", “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon MannKind’s current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the risks detailed in MannKind’s filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2016 and subsequent periodic reports on Form 10-Q and current reports on Form 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.
Company Contact: Rose Alinaya SVP, Investor Relations 661-775-5300 email@example.com